Article

No Benefit of Steroids for Spinal Stenosis in Randomized Trial

The study showed no long-term benefit of glucocorticoid injections for spinal stenosis, calling some preoperative insurance requirements into question.

Friedly JL, Comstock BA, Turner JA, et al.A Randomized Trial of Epidural Glucocorticoid Injections for Spinal StenosisN Engl J Med (2014) 371:11-21 July 3, 2014 doi: 10.1056/NEJMoa1313265

Andersson GBJ. Editorial: Epidural Glucocorticoid Injections in Patients with Lumbar Spinal Stenosis.N Engl J Med  (2014) 371:75-76 July 3, 2014 doi: 10.1056/NEJMe1405475

Lamas D Glucocorticoid Injections for Spinal StenosisNow@NEJM. July 2, 2014

Glucorticoids had no clinically significant benefit over placebo after six weeks for 400 patients with lumbar central spinal stenosis and moderate-to-severe leg pain and disability, the primary outcomes of the study.

The editorial recommends informing patients about the lack of evidence and risks.

There were small differences in favor of glucocorticoids in secondary outcomes, subgroup analyses and post-hoc analysis. For example, glucocorticoids had a (statistically significant but clinically insignificant) improvement in pain and disability at 3 weeks, but not at 6 weeks.

Conversely, there were more (minor, reversible) reported adverse events in the glucocorticoid group, but serious adverse events were rare. Glucocorticoid injections can have catastrophic complications in the community, which were beyond the scope of this study.

Many insurance companies require epidural injections as part of nonsurgical treatment before surgery is approved. The editorial suggests that this requirement be “reconsidered.”

Four hundred patients were randomized to receive either epidural injections of glucocorticoids plus lidocaine or lidocaine alone. The primary outcomes were the score on the Roland-Morris Disability Questionnaire and a rating of 1 to 10 on a leg pain intensity scale. At six weeks, there was improvement in both primary outcomes, pain and disability, but the differences between the groups was not statistically significant.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.